Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q2 2016 · 10-Q
Revenue$1.91M$1.91M+12.2% vs Q2 2015 Net Income-$591.93K-$591.93KN/M vs Q2 2015 EPS, diluted—
Gross Profit$990,467+20.3% Operating Income-$602,515N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$108,710−31.8% Free Cash Flowderived$103,408— Margins · derivedGross margin51.8%+3.5 pt vs Q2 2015
Operating margin-31.5%−22.3 pt vs Q2 2015
Net margin-30.9%−21.7 pt vs Q2 2015
ended Jun 30, 2016 · filed Aug 8, 2016 · 39 d after period end